Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: The pan-american collaborative retina study

Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (IVB) (Avastin; Genentech Inc., San Francisco, CA) (1.25 or 2.5 mg) in patients with subfoveal choroidal neovascularizat...

Descripción completa

Detalles Bibliográficos
Autores Principales: Arevalo, J. Fernando, Sánchez, Juan G., Wu, Lihteh, Berrocal, Maria H., Alezzandrini, Arturo A., Restrepo, Natalia, Maia, Mauricio, Farah, Michel E., Brito, Miguel, Díaz-Llopis, Manuel, Rodríguez, Francisco J., Reategui, Guillermo, Iturralde-Iraola, Juan, Udaondo-Mirete, Patricia, Group, Pan-American Collaborative Retina Study
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: Elsevier Inc. 2010
Materias:
Acceso en línea:https://repository.urosario.edu.co/handle/10336/22732
https://doi.org/10.1016/j.ophtha.2010.01.056